11 3D Printer pharmaceutical companies in the world

In 1996, Professor Michael Cima of the Massachusetts Institute of Technology first reported that 3D Printer technology could be applied to pharmaceuticals. The technology has unique advantages in terms of cost and customization, attracting many university laboratories and pharmaceutical companies for research and development.

In July 2015, Spritam, the first 3D Printer drug product developed by Aprecia in the United States using drug powder bonding technology, was approved by the FDA. The approval of this product marks the approval of the 3D Printer pharmaceutical technology by the regulatory authorities.

According to Research and Markets market research, Asia Pacific is expected to account for a 34.1% market share of 3D Printer pharmaceuticals in 2024, growing at a CAGR of 18.2% over the forecast period. The Chinese 3D Printer drug market was valued at USD 67.3 million in 2016 and is expected to reach USD 252 million by the end of 2024. Increasing demand for fast-dissolving pharmaceuticals is a key factor contributing to the growth of the global 3D Printer pharmaceuticals market.

The much higher than global growth rate in the Asia-Pacific region can be attributed firstly to the continued growth in the GDP of the countries in the Asia-Pacific region and the strong expansion of the pharmaceutical industry; in addition, the increasing consumer demand for advanced medical technology in the context of rising disposable incomes, Will drive the growth of the 3D Printer pharmaceutical market.

3D Printer medicine opens the door to on-demand production of personalized medicines, subverts the traditional slow drug iteration process, provides a new idea for innovation in the pharmaceutical industry, and opens up a new blue ocean. According to incomplete statistics from Zero One Think Tank, dozens of players have emerged on this track, including AstraZeneca, Bayer, MSD and other large pharmaceutical companies. Due to the lack of public information, this article only summarizes 11 drug 3D Printer companies that have achieved initial results.

Table 1: Summary of 11 Pharmaceutical 3D Printer Companies

Data source: official website of the company, Zero One Think Tank

Among the above 11 companies, 6 companies have been established in the past 10 years. Although based on the emerging medical technology track, the overall financing situation is not optimistic. Except for the well-known pharmaceutical companies Merck KgaA, GlaxoSmithKline and Pfizer, only half of the other companies have received financing. Aprecia Pharmaceuticals is both the first company to have its product approved by the FDA and the company with the largest number of financings. Craft Health, the latest established company, is also one of the four companies to receive financing.

Table 2: Summary of financing of 4 3D drug printing companies

Data source: crunchbase, Zero One Think Tank

The above-mentioned 11 companies have a relatively short establishment time or 3D Printer drug technology research and development investment time, and are more dependent on the achievements of universities and scientific research institutions. Except for Laxxon Medical, almost all the other companies’ products are based on traditional technologies such as MED, SLS, and FDM, which means that 3D printing The new technology research and development of the Printer drug track will be the focus of the enterprise.

Although various parties predict a promising market for 3D Printer drugs, there are multiple challenges to promote this technology into the medical scene. In the short term, there is still a long way to go for 3D Printer medicine machines to retail or realize the idea of patients printing medicines at home. However, with the continuous trial and release of 3D Printer medicine technology approval in various countries and the continuous breakthrough of medicine printing technology, 3D Printer medicines are still the future pharmacy. As well as the innovative way of personalized medicine at home, it will meet the needs of different groups of people for medicines, and achieve linkage effects such as personalized remote medicine for doctors and patients.

Source: Zero One Finance Baijiahao